阿利西尤单抗联合重组人脑利钠肽治疗急性ST段抬高型心肌梗死合并心力衰竭的临床观察

扫码查看

原文链接

国家科技期刊平台
NETL
NSTL
万方数据

中文摘要：目的:探究阿利西尤单抗联合重组人脑利钠肽(rhBNP)治疗急性ST段抬高型心肌梗死(STEMI)合并心力衰竭(HF)的临床效果。方法:选取 2021 年 1 月—2023 年 4 月广东医科大学附属第二医院收治的 92 例STEMI合并HF患者作为研究对象，采用随机数表法分为对照组(n=46)和观察组(n=46)。在常规治疗基础上，对照组予以rhBNP治疗，观察组予以阿利西尤单抗联合rhBNP治疗，两组均获得 6 个月随访，比较两组疗效、主要不良心血管事件(MACE)发生率，于治疗前后，对比两组心功能指标[左心室射血分数(LVEF)、左室舒张末径(LVEDD)、左心室收缩末径(LVESD)]、血脂指标。结果:与对照组比较，观察组总有效率更高，MACE发生率更低，差异有统计学意义(P<0。05);治疗后，两组LVEF升高，LVEDD、LVESD值及血脂指标均下降，且观察组改善更明显，差异有统计学意义(P<0。05)。结论:阿利西尤单抗联合rhBNP治疗STEMI合并HF可提高疗效，改善血脂指标，提高心功能，降低MACE发生率。

外文标题：Clinical Observation of Aliciumab Combined with Recombinant Human Brain Natriuretic Peptide in the Treatment of Acute ST Segment Elevation Myocardial Infarction with Heart Failure

外文摘要：Objective:Exploring the clinical efficacy of combination therapy with alloxiumab and recombinant human brain natriuretic peptide(rhBNP)in the treatment of acute ST segment elevation myocardial infarction(STEMI)with heart failure(HF).Method:92 patients with STEMI combined with HF,admitted to the Second Affiliated Hospital of Guangdong Medical University from January 2021 to April 2023,were selected as the study objects and randomly divided into a control group(n=46)and an observation group(n=46)according to random number table method.On the basis of conventional treatment,the control group received rhBNP treatment,while the observation group received a combination of alexiumab and rhBNP treatment.Patients of the two groups were followed up for 6 months,and the efficacy and incidence of major adverse cardiovascular events(MACE)were compared between the two groups.The cardiac function indicators[left ventricular ejection fraction(LVEF),left ventricular end diastolic diameter(LVEDD),left ventricular end systolic diameter(LVESD)]and blood lipid indicators before and after treatment were compared between the two groups.Result:Compared with the control group,the observation group had a higher overall effective rate and a lower incidence of MACE,with a statistically significant difference(P<0.05).After treatment,LVEF increased in both groups,while LVEDD,LVESD values,and blood lipid indicators decreased.The observation group showed more significant improvement,and the difference was statistically significant(P<0.05).Conclusion:The combination of Aliciumab and rhBNP in the treatment of STEMI with HF can improve efficacy,improve blood lipid indicators,enhance heart function,and reduce the incidence of MACE.

外文关键词：

Acute ST segment elevation myocardial infarctionHeart failureRecombinant human brain natriuretic peptideAlizumabCardiac function

作者：

郭英杰、许锦荣、陈晓欣、刘左玲

展开 >

作者单位：

广东医科大学附属第二医院广东湛江 524000

关键词：

急性ST段抬高型心肌梗死心力衰竭重组人脑利钠肽阿利西尤单抗心功能

出版年：

2024

DOI：